National survey of drug-resistant tuberculosis in China.

BACKGROUND The available information on the epidemic of drug-resistant tuberculosis in China is based on local or regional surveys. In 2007, we carried out a national survey of drug-resistant tuberculosis in China. METHODS We estimated the proportion of tuberculosis cases in China that were resistant to drugs by means of cluster-randomized sampling of tuberculosis cases in the public health system and testing for resistance to the first-line antituberculosis drugs isoniazid, rifampin, ethambutol, and streptomycin and the second-line drugs ofloxacin and kanamycin. We used the results from this survey and published estimates of the incidence of tuberculosis to estimate the incidence of drug-resistant tuberculosis. Information from patient interviews was used to identify factors linked to drug resistance. RESULTS Among 3037 patients with new cases of tuberculosis and 892 with previously treated cases, 5.7% (95% confidence interval [CI], 4.5 to 7.0) and 25.6% (95% CI, 21.5 to 29.8), respectively, had multidrug-resistant (MDR) tuberculosis (defined as disease that was resistant to at least isoniazid and rifampin). Among all patients with tuberculosis, approximately 1 of 4 had disease that was resistant to isoniazid, rifampin, or both, and 1 of 10 had MDR tuberculosis. Approximately 8% of the patients with MDR tuberculosis had extensively drug-resistant (XDR) tuberculosis (defined as disease that was resistant to at least isoniazid, rifampin, ofloxacin, and kanamycin). In 2007, there were 110,000 incident cases (95% CI, 97,000 to 130,000) of MDR tuberculosis and 8200 incident cases (95% CI, 7200 to 9700) of XDR tuberculosis. Most cases of MDR and XDR tuberculosis resulted from primary transmission. Patients with multiple previous treatments who had received their last treatment in a tuberculosis hospital had the highest risk of MDR tuberculosis (adjusted odds ratio, 13.3; 95% CI, 3.9 to 46.0). Among 226 previously treated patients with MDR tuberculosis, 43.8% had not completed their last treatment; most had been treated in the hospital system. Among those who had completed treatment, tuberculosis developed again in most of the patients after their treatment in the public health system. CONCLUSIONS China has a serious epidemic of drug-resistant tuberculosis. MDR tuberculosis is linked to inadequate treatment in both the public health system and the hospital system, especially tuberculosis hospitals; however, primary transmission accounts for most cases. (Funded by the Chinese Ministry of Health.).

[1]  Eliza Barclay,et al.  Text messages could hasten tuberculosis drug compliance , 2009, The Lancet.

[2]  Q. Gao,et al.  Drug-resistant tuberculosis in Shanghai, China, 2000-2006: prevalence, trends and risk factors. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  W. Jack,et al.  Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial , 2010, The Lancet.

[4]  E. Waldman,et al.  A population-based study of drug resistance and transmission of tuberculosis in an urban community. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  J. Bayona,et al.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis , 2010, The Lancet.

[6]  D. Menzies,et al.  Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. , 2008, American journal of respiratory and critical care medicine.

[7]  M. Uplekar,et al.  Engaging all health care providers in TB control. Guidance on implementing public-private mix approaches. , 2006 .

[8]  K. Kliiman,et al.  Predictors of Extensively Drug-Resistant Pulmonary Tuberculosis , 2009, Annals of Internal Medicine.

[9]  P HAUDUROY,et al.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. , 1963, Bulletin of the World Health Organization.

[10]  D. Chin,et al.  Progress in tuberculosis control and the evolving public-health system in China , 2007, The Lancet.

[11]  S. Munsiff,et al.  Risk factors for drug-resistant tuberculosis among non-US-born persons in New York City. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  K. Kam,et al.  Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance , 2009, The Lancet.

[13]  H. Blumberg,et al.  Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[14]  A. Nunn,et al.  Global tuberculosis drug development pipeline: the need and the reality , 2010, The Lancet.

[15]  M. Pai,et al.  Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis , 2008, Annals of Internal Medicine.

[16]  R. Chaisson,et al.  Prevalence of anti-tuberculosis drug resistance in an HIV/AIDS reference hospital in Rio de Janeiro, Brazil. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  H. Yanai,et al.  Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. , 2004, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  Eduardo Gotuzzo,et al.  Rapid molecular detection of tuberculosis and rifampin resistance. , 2010, The New England journal of medicine.

[19]  N. Binkin,et al.  Determinants of drug-resistant tuberculosis: analysis of 11 countries. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[20]  Madhukar Pai,et al.  Tuberculosis diagnosis--time for a game change. , 2010, The New England journal of medicine.

[21]  K. Floyd,et al.  MDR tuberculosis--critical steps for prevention and control. , 2010, The New England journal of medicine.

[22]  Christopher Dye,et al.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.

[23]  V. Boonsarngsuk,et al.  Thai drug-resistant tuberculosis predictive scores. , 2009, Singapore medical journal.

[24]  J. Caminero Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  A. Benedetti,et al.  Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis , 2009, PLoS medicine.

[26]  M. Aziz,et al.  Guidelines for surveillance of drug resistance in tuberculosis , 2009 .